Harrison Nguyen, MD, MBA, MPH, FAAD, the managing director of Harrison Dermatology and Research Group and clinical assistant professor of dermatology at the University of Houston College of Medicine in Houston, Texas, discusses using the DecisionDx-Melanoma test to guide treatment for patients with melanoma. He explains how the test goes beyond traditional staging by combining clinical and pathological data with the tumor’s genomic profile to better predict the risk of sentinel lymph node involvement and melanoma recurrence. Dr. Nguyen also highlights how this information helps guide more personalized conversations with patients about their treatment and follow-up plans.
Topics Covered:
- Individualized risk assessment for sentinel lymph node biopsy
- Monitoring patients with negative sentinel lymph node biopsy
- Impact of DecisionDx-Melanoma test on patient outcomes
Explore Related Resources:
Assessing the Prognostic Significance of the 31-gene Expression Profile Test
Identifying the Risk of Central Nervous System Metastasis Using the 31-Gene Expression Profile Test
